Vanguard Group Portfolio holdings
Vanguard Group is an investment manager owned by the funds it manages, and so by its own customers. John Bogle founded it in 1975 and is credited with creating the first index fund available to individual investors. After Wellington Management fired Bogle in 1974, he started a new fund division there and named it Vanguard after HMS Vanguard, Horatio Nelson's flagship. Bogle set up its first index fund in 1976, the fund that became the Vanguard 500 Index Fund, and the firm added a bond index fund in 1986. It began offering ETFs in 2001 as exchange-traded shares of its index funds, and it also serves employers' retirement plans and independent financial advisers. Salim Ramji, who came from BlackRock, was named chief executive in 2024 as the first outsider to lead the firm.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$8.03B |
| 2 |
Microsoft
MSFT
|
+$8B |
| 3 |
Apple
AAPL
|
+$7.21B |
| 4 |
TotalEnergies
TTE
|
+$5.18B |
| 5 |
Meta Platforms (Facebook)
META
|
+$4.85B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kellanova
K
|
+$2.74B |
| 2 |
DuPont de Nemours
DD
|
+$2.65B |
| 3 |
Mr. Cooper
COOP
|
+$1.41B |
| 4 |
Interpublic Group of Companies
IPG
|
+$1.24B |
| 5 |
Amazon
AMZN
|
+$1.13B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32% |
| 2 | Financials | 13.5% |
| 3 | Consumer Discretionary | 9.9% |
| 4 | Healthcare | 9.82% |
| 5 | Communication Services | 9.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1551
Immunovant
IMVT
$7.27B
| $198M | ﹤0.01% |
7,779,314
+952,504
| +14% | +$21.2M |
2020 Q2
22 quarters
|
|
1552
DELISTED
Catalyst Pharmaceutical
CPRX
| $197M | ﹤0.01% |
8,432,247
-281,273
| -3% | -$6.27M |
2013 Q2
50 quarters
|
|
1553
Pebblebrook Hotel Trust
PEB
$2.43B
| $197M | ﹤0.01% |
17,371,906
-506,793
| -3% | -$5.58M |
2013 Q2
50 quarters
|
|
1554
Grupo Cibest SA
CIB
$22.4B
| $197M | ﹤0.01% |
3,089,670
+67,986
| +2% | +$4.07M |
2013 Q2
50 quarters
|
|
1555
Tarsus Pharmaceuticals
TARS
$3.49B
| $196M | ﹤0.01% |
2,399,560
+127,470
| +6% | +$9.5M |
2020 Q4
20 quarters
|
|
1556
Supernus, Inc. Common Stock
SUPN
$1.61B
| $196M | ﹤0.01% |
5,473,891
+2,008,078
| +58% | +$61.3M |
2023 Q2
10 quarters
|
|
1557
ACM Research
ACMR
$3.41B
| $196M | ﹤0.01% |
4,972,103
+125,690
| +3% | +$4.68M |
2018 Q1
31 quarters
|
|
1558
Northwest Bancshares
NWBI
$2.25B
| $196M | ﹤0.01% |
16,337,481
-168,454
| -1% | -$2.05M |
2013 Q2
50 quarters
|
|
1559
Avis
CAR
$4.51B
| $196M | ﹤0.01% |
1,525,988
-16,107
| -1% | -$2.25M |
2013 Q2
50 quarters
|
|
1560
Marriott Vacations Worldwide
VAC
$3.98B
| $196M | ﹤0.01% |
3,392,787
+234,105
| +7% | +$13.8M |
2013 Q2
50 quarters
|
|
1561
Comstock Resources
CRK
$4.23B
| $196M | ﹤0.01% |
8,443,068
-112,691
| -1% | -$2.48M |
2013 Q2
50 quarters
|
|
1562
Werner Enterprises
WERN
$1.67B
| $195M | ﹤0.01% |
6,514,200
+90,480
| +1% | +$2.49M |
2013 Q2
50 quarters
|
|
1563
Summit Therapeutics
SMMT
$14.3B
| $195M | ﹤0.01% |
11,177,220
-202,508
| -2% | -$3.81M |
2020 Q4
20 quarters
|
|
1564
C3.ai
AI
$1.9B
| $195M | ﹤0.01% |
14,469,953
+108,011
| +0.8% | +$1.72M |
2020 Q4
20 quarters
|
|
1565
Alkami Technology
ALKT
$1.52B
| $194M | ﹤0.01% |
8,414,419
+456,275
| +6% | +$10.1M |
2021 Q2
18 quarters
|
|
1566
AtriCure
ATRC
$2.94B
| $194M | ﹤0.01% |
4,903,755
+62,861
| +1% | +$2.3M |
2013 Q2
50 quarters
|
|
1567
National Healthcare
NHC
$3.29B
| $194M | ﹤0.01% |
1,411,936
-10,261
| -0.7% | -$1.33M |
2013 Q2
50 quarters
|
|
1568
Levi Strauss
LEVI
$9.24B
| $193M | ﹤0.01% |
9,320,747
+342,009
| +4% | +$7.37M |
2019 Q1
27 quarters
|
|
1569
Recursion Pharmaceuticals
RXRX
$2.21B
| $193M | ﹤0.01% |
47,187,759
+7,407,606
| +19% | +$36.7M |
2021 Q2
18 quarters
|
|
1570
TAL Education Group
TAL
$5.65B
| $193M | ﹤0.01% |
17,671,668
+277,473
| +2% | +$3.15M |
2015 Q4
40 quarters
|
|
1571
First Commonwealth Financial
FCF
$2.05B
| $193M | ﹤0.01% |
11,429,416
-89,820
| -0.8% | -$1.47M |
2013 Q2
50 quarters
|
|
1572
Banc of California
BANC
$2.87B
| $192M | ﹤0.01% |
9,951,795
+438,320
| +5% | +$7.85M |
2013 Q3
49 quarters
|
|
1573
Worthington Enterprises
WOR
$3.09B
| $191M | ﹤0.01% |
3,696,701
-56,733
| -2% | -$3.13M |
2013 Q2
50 quarters
|
|
1574
Arcus Biosciences
RCUS
$2.73B
| $190M | ﹤0.01% |
7,962,874
+1,333,421
| +20% | +$27.2M |
2018 Q1
31 quarters
|
|
1575
Goosehead Insurance
GSHD
$1.3B
| $189M | ﹤0.01% |
2,564,899
-23,843
| -0.9% | -$1.7M |
2018 Q2
30 quarters
|
|
Similar funds
Vanguard Group's Q4 2025 Portfolio in Review
As of Q4 2025, Vanguard Group held 4,426 positions worth $6.9T, up 3.3% from $6.68T the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Trading was light in Q4 2025: portfolio turnover was 4.1%. Vanguard Group opened 82 new positions and exited 98, leaving the 4,426-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 32% of assets, down from 32% a quarter earlier, followed by Financials and Consumer Discretionary.
- Vanguard Group's largest Q4 2025 buy was TotalEnergies: 81,863,403 shares worth $5.34B.
- Vanguard Group added most to NVIDIA in Q4 2025, an estimated $8.03B increase.
- Vanguard Group's biggest Q4 2025 reduction was DuPont de Nemours, cutting an estimated $2.65B.
- Vanguard Group fully exited Kellanova in Q4 2025, selling an estimated $2.74B.
- Vanguard Group's ten largest holdings make up 31% of its $6.9T portfolio in Q4 2025.
- Vanguard Group opened 82 new positions and closed 98 in Q4 2025.
- Vanguard Group's portfolio value rose 3.3% quarter-over-quarter to $6.9T.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.